HSV-1 Oncolytic Virus Targeting CEACAM6-Expressing Tumors Using a Bispecific T-Cell Engager
Murad, Y. M.; Lee, I.-F.; Liu, X.; Delwar, Z.; Ding, J.; Liu, G.; Tatsiy, O.; Chouljenko, D.; Hussack, G.; Van Faassen, H.; Jia, W. W.-G.
Show abstract
VG21306 is a novel oncolytic virus (OV) that encodes a secretable bispecific T-cell engager targeting Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6)-expressing tumors. Delivering a T-cell engager locally to a tumor mass will circumvent physical barriers that prevent antibodies from penetrating the tumor, and will mitigate the off-tumor, on-target toxicity risk. Both in vitro and in vivo testing demonstrated the expression of a functional T-cell engager capable of binding both targets. The efficacy of the engager was demonstrated in vitro, where addition of the engager payload to the OV enhanced anti-tumor efficacy against tumor cells overexpressing CEACAM6. Moreover, we have demonstrated the engagers ability to induce bystander killing in cells lacking CEACAM6 expression, as well as engaging exhausted T cells and inducing tumor cell death. The safety of the engager was demonstrated by the lack of binding to normal human tissue or normal tissue adjacent to tumors, as well as the absence of any measurable leakage of the expressed engager into the blood of mice treated by intratumoral OV injection.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 Permissive Glioblastoma Cell Line for High Throughput Antiviral Screening 93%
- DMBT1 promotes SARS-CoV-2 infection and its SRCR-derived peptide inhibits SARS-CoV-2 infection 93%
- A Novel High-Throughput Single B-Cell Cloning Platform for Isolation and Characterization of High-Affinity and potent SARS-CoV-2 Neutralizing Antibodies 92%
Similar papers in this journal
- Elucidating Mechanisms of Antitumor Immunity Mediated by Live Oncolytic Vaccinia and Heat-Inactivated Vaccinia 93%
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 93%
- HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancer 93%
Similar papers in this journal
- Strong SARS-CoV-2 N-specific CD8+ T immunity induced by engineered extracellular vesicles associates with protection from lethal infection in mice. 94%
- Receptor binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2 93%
- ZRC3308 monoclonal antibody cocktail shows protective efficacy in Syrian hamsters against SARS-CoV-2 infection 93%
Similar papers in this journal
- Self-multimerization of mRNA LNP-derived antigen improves antibody responses 94%
- Multivalent Exosome based protein vaccine: a "mix and match" approach to epidemic viruses' challenges. 93%
- Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses 93%
Similar papers in this journal
- CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells 94%
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2 93%
- Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.